Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab<i>in Utero</i>: A Prospective Cohort Study in 107 Children

Abstract

Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.